Exogen
This article was originally published in The Gray Sheet
Executive Summary
Closes $10 mil. private financing from combination of new investors and investors who participated in the West Caldwell, New Jersey firm's March 1993 $7.3 mil. initial private financing round. The company says the proceeds will "support an effective launch" of its Sonic Accelerated Fracture Healing System (SAFHS), which recently received premarket approval from FDA for the accelerated healing of new fractures in the lower arm and leg ("The Gray Sheet" Oct. 17, p. 10). Exogen also will use the funds to support clinical investigation of additional indications for SAFHS, such as treatment of hip fractures, spine fusions, and bony ingrowth into artificial joint replacements